Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
J Rheumatol
; 32(11): 2183-5, 2005 Nov.
Article
em En
| MEDLINE
| ID: mdl-16265699
ABSTRACT
OBJECTIVE:
To report early experience of switching anti-tumor necrosis factor-a (TNF-alpha) therapy from infliximab to etanercept in patients with spondyloarthropathy (SpA) and psoriatic arthritis (PsA).METHODS:
Thirteen patients with various SpA (7 with ankylosing spondylitis and 6 with undifferentiated SpA) and 2 patients with PsA were receiving infliximab. Because they were experiencing inadequate response or adverse events, therapy was changed to etanercept. Patients were evaluated for response to the change in anti-TNF-alpha therapy at baseline, after 3 months, and then every 6 months.RESULTS:
During the mean 10-month followup after the change in therapy, 9 of 13 patients with SpA and both patients with PsA responded to etanercept and none experienced intolerance to this agent.CONCLUSION:
These data suggest that switching between anti-TNF-alpha drugs may be useful for patients with SpA who are unresponsive or intolerant to a first anti-TNF-alpha agent.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulina G
/
Artrite Psoriásica
/
Receptores do Fator de Necrose Tumoral
/
Antirreumáticos
/
Espondiloartropatias
/
Anticorpos Monoclonais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Rheumatol
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
França